DBV Technologies S.A. (EPA:DBV)
France · Delayed Price · Currency is EUR 2.098
-0.166 (-7.33%)
Sep 11, 2026, 5:35 PM CET
DBV Technologies Market Cap
DBV Technologies has a market cap or net worth of €620.83 million as of September 11, 2026. Its market cap has increased by 187.67% in one year.
Market Cap
620.83M
Enterprise Value
474.48M
Revenue
4.41M
Ranking
n/a
PE Ratio
n/a
Stock Price
€2.10
ChartMarket Cap Chart
Since March 29, 2012, DBV Technologies's market cap has increased from 79.23M to 620.83M, an increase of 683.60%. That is a compound annual growth rate of 15.30%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 11, 2026 | 620.83M | -8.44% |
| Dec 31, 2025 | 678.09M | 949.56% |
| Dec 31, 2024 | 64.61M | -63.70% |
| Dec 29, 2023 | 177.98M | -39.80% |
| Dec 30, 2022 | 295.62M | 75.76% |
| Dec 31, 2021 | 168.19M | -29.23% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Nanobiotix | 1.65B |
| Inventiva | 951.03M |
| MedinCell | 811.60M |
| Genfit | 615.30M |
| Valneva SE | 563.82M |
| Valerio Therapeutics Société anonyme | 355.61M |
| Transgene | 242.11M |
| Cellectis | 205.01M |